ArticleThe Lancet regional health. Western Pacific2024

Efficacy and safety of visepegenatide, a long-acting weekly GLP-1 receptor agonist as monotherapy in type 2 diabetes mellitus: a randomised, double-blind, parallel, placebo-controlled phase 3 trial.

Xiang Yan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.